companydirectorylist.com  Global Business Directory e directory aziendali
Ricerca Società , Società , Industria :


elenchi dei paesi
USA Azienda Directories
Canada Business Elenchi
Australia Directories
Francia Impresa di elenchi
Italy Azienda Elenchi
Spagna Azienda Directories
Svizzera affari Elenchi
Austria Società Elenchi
Belgio Directories
Hong Kong Azienda Elenchi
Cina Business Elenchi
Taiwan Società Elenchi
Emirati Arabi Uniti Società Elenchi


settore Cataloghi
USA Industria Directories














  • Abemaciclib - Wikipedia
    Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6
  • Abemaciclib for Breast Cancer: Uses, Dosage, Side Effects . . .
    Abemaciclib is used to treat HR-positive and HER2-negative breast cancer in adults It is a targeted treatment, not a chemotherapy drug The brand name of abemaciclib is Verzenio
  • Abemaciclib (oral route) - Mayo Clinic
    Abemaciclib is used together with tamoxifen or an aromatase inhibitor (eg, anastrozole, exemestane, letrozole) to treat hormone receptor (HR)-positive, HER-2 negative, node-positive, early breast cancer with a high risk of coming back as determined by your doctor
  • Abemaciclib (Verzenios) - Breast Cancer Now
    Abemaciclib is a targeted or biological therapy drug When used to treat breast cancer, abemaciclib is taken alongside hormone (endocrine) therapy Abemaciclib is the drug’s non-branded name Its brand name is Verzenios It belongs to a group of drugs called CDK (cyclin dependent kinase) inhibitors
  • Abemaciclib - NCI - National Cancer Institute
    Abemaciclib works by blocking the activity of proteins called CDK4 and CDK6 that control how fast cells grow Blocking these proteins may slow or stop the growth of cancer cells Abemaciclib is a type of targeted therapy drug called a kinase inhibitor
  • FDA expands early breast cancer indication for abemaciclib . . .
    On March 3, 2023, the Food and Drug Administration (FDA) approved abemaciclib (Verzenio, Eli Lilly and Company) with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant
  • Abemaciclib - Chemocare
    ABEMACICLIB (a BEM a SYE klib) treats breast cancer It works by blocking a protein that causes cancer cells to grow and multiply This helps to slow or stop the spread of cancer cells
  • Abemaciclib: MedlinePlus Drug Information
    Abemaciclib is used in combination with tamoxifen (Soltamox) or an aromatase inhibitor such as anastrozole (Arimidex), exemestane (Aromasin), or letrozole (Femara) to treat a certain type of hormone receptor-positive, early breast cancer




Annuari commerciali , directory aziendali
Annuari commerciali , directory aziendali copyright ©2005-2012 
disclaimer